Enhanced methylglyoxal formation in the erythrocytes of hemodialyzed patients

E. Karg, Ferenc Papp, Noemi Tassi, T. Janáky, G. Wittmann, S. Túri

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Methylglyoxal (MG) contributes significantly to the carbonyl stress in uremia; however, the reason for its increased concentration is not clear. Thus, the present study was aimed to investigate the formation and degradation of MG in the erythrocytes of hemodialyzed (HD) patients with end-stage renal disease. In 22 nondiabetic patients on long-term HD, erythrocyte MG and d-lactate levels, glyoxalase activities, and whole blood reduced glutathione content were determined. The data were compared with those from 22 healthy controls. Erythrocyte MG and d-lactate production were also investigated in vitro under normoglycemic (5 mmol/L) and hyperglycemic (50 mmol/L) conditions. The erythrocyte MG levels were elevated (P <.001) in the HD patients. The blood reduced glutathione content and glyoxalase I activity were similar to the control levels, but the glyoxalase II activity was significantly (P <.005) increased. In the normoglycemic in vitro model, production of both MG (P <.001) and d-lactate (P <.002) was significantly enhanced in the HD erythrocytes relative to the controls. During hyperglycemia, the MG formation and degradation rates were further increased (P <.001). The present study demonstrated an increased formation of MG in the erythrocytes of HD patients. This seemed to be related to a glucose metabolism disturbance of the cells. The degradation system of MG was also activated; still, it was not able to counteract the high rate of MG formation. The alterations and imbalance of these metabolic processes may contribute to the carbonyl overload and stress in the HD patients.

Original languageEnglish
Pages (from-to)976-982
Number of pages7
JournalMetabolism: Clinical and Experimental
Volume58
Issue number7
DOIs
Publication statusPublished - Jul 2009

Fingerprint

Pyruvaldehyde
Erythrocytes
Lactic Acid
hydroxyacylglutathione hydrolase
Glutathione
Lactoylglutathione Lyase
Uremia
Hyperglycemia
Chronic Kidney Failure

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Enhanced methylglyoxal formation in the erythrocytes of hemodialyzed patients. / Karg, E.; Papp, Ferenc; Tassi, Noemi; Janáky, T.; Wittmann, G.; Túri, S.

In: Metabolism: Clinical and Experimental, Vol. 58, No. 7, 07.2009, p. 976-982.

Research output: Contribution to journalArticle

@article{6e3f8595b18e434eb82e5c20be399bac,
title = "Enhanced methylglyoxal formation in the erythrocytes of hemodialyzed patients",
abstract = "Methylglyoxal (MG) contributes significantly to the carbonyl stress in uremia; however, the reason for its increased concentration is not clear. Thus, the present study was aimed to investigate the formation and degradation of MG in the erythrocytes of hemodialyzed (HD) patients with end-stage renal disease. In 22 nondiabetic patients on long-term HD, erythrocyte MG and d-lactate levels, glyoxalase activities, and whole blood reduced glutathione content were determined. The data were compared with those from 22 healthy controls. Erythrocyte MG and d-lactate production were also investigated in vitro under normoglycemic (5 mmol/L) and hyperglycemic (50 mmol/L) conditions. The erythrocyte MG levels were elevated (P <.001) in the HD patients. The blood reduced glutathione content and glyoxalase I activity were similar to the control levels, but the glyoxalase II activity was significantly (P <.005) increased. In the normoglycemic in vitro model, production of both MG (P <.001) and d-lactate (P <.002) was significantly enhanced in the HD erythrocytes relative to the controls. During hyperglycemia, the MG formation and degradation rates were further increased (P <.001). The present study demonstrated an increased formation of MG in the erythrocytes of HD patients. This seemed to be related to a glucose metabolism disturbance of the cells. The degradation system of MG was also activated; still, it was not able to counteract the high rate of MG formation. The alterations and imbalance of these metabolic processes may contribute to the carbonyl overload and stress in the HD patients.",
author = "E. Karg and Ferenc Papp and Noemi Tassi and T. Jan{\'a}ky and G. Wittmann and S. T{\'u}ri",
year = "2009",
month = "7",
doi = "10.1016/j.metabol.2009.02.032",
language = "English",
volume = "58",
pages = "976--982",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "7",

}

TY - JOUR

T1 - Enhanced methylglyoxal formation in the erythrocytes of hemodialyzed patients

AU - Karg, E.

AU - Papp, Ferenc

AU - Tassi, Noemi

AU - Janáky, T.

AU - Wittmann, G.

AU - Túri, S.

PY - 2009/7

Y1 - 2009/7

N2 - Methylglyoxal (MG) contributes significantly to the carbonyl stress in uremia; however, the reason for its increased concentration is not clear. Thus, the present study was aimed to investigate the formation and degradation of MG in the erythrocytes of hemodialyzed (HD) patients with end-stage renal disease. In 22 nondiabetic patients on long-term HD, erythrocyte MG and d-lactate levels, glyoxalase activities, and whole blood reduced glutathione content were determined. The data were compared with those from 22 healthy controls. Erythrocyte MG and d-lactate production were also investigated in vitro under normoglycemic (5 mmol/L) and hyperglycemic (50 mmol/L) conditions. The erythrocyte MG levels were elevated (P <.001) in the HD patients. The blood reduced glutathione content and glyoxalase I activity were similar to the control levels, but the glyoxalase II activity was significantly (P <.005) increased. In the normoglycemic in vitro model, production of both MG (P <.001) and d-lactate (P <.002) was significantly enhanced in the HD erythrocytes relative to the controls. During hyperglycemia, the MG formation and degradation rates were further increased (P <.001). The present study demonstrated an increased formation of MG in the erythrocytes of HD patients. This seemed to be related to a glucose metabolism disturbance of the cells. The degradation system of MG was also activated; still, it was not able to counteract the high rate of MG formation. The alterations and imbalance of these metabolic processes may contribute to the carbonyl overload and stress in the HD patients.

AB - Methylglyoxal (MG) contributes significantly to the carbonyl stress in uremia; however, the reason for its increased concentration is not clear. Thus, the present study was aimed to investigate the formation and degradation of MG in the erythrocytes of hemodialyzed (HD) patients with end-stage renal disease. In 22 nondiabetic patients on long-term HD, erythrocyte MG and d-lactate levels, glyoxalase activities, and whole blood reduced glutathione content were determined. The data were compared with those from 22 healthy controls. Erythrocyte MG and d-lactate production were also investigated in vitro under normoglycemic (5 mmol/L) and hyperglycemic (50 mmol/L) conditions. The erythrocyte MG levels were elevated (P <.001) in the HD patients. The blood reduced glutathione content and glyoxalase I activity were similar to the control levels, but the glyoxalase II activity was significantly (P <.005) increased. In the normoglycemic in vitro model, production of both MG (P <.001) and d-lactate (P <.002) was significantly enhanced in the HD erythrocytes relative to the controls. During hyperglycemia, the MG formation and degradation rates were further increased (P <.001). The present study demonstrated an increased formation of MG in the erythrocytes of HD patients. This seemed to be related to a glucose metabolism disturbance of the cells. The degradation system of MG was also activated; still, it was not able to counteract the high rate of MG formation. The alterations and imbalance of these metabolic processes may contribute to the carbonyl overload and stress in the HD patients.

UR - http://www.scopus.com/inward/record.url?scp=66349099283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66349099283&partnerID=8YFLogxK

U2 - 10.1016/j.metabol.2009.02.032

DO - 10.1016/j.metabol.2009.02.032

M3 - Article

VL - 58

SP - 976

EP - 982

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 7

ER -